Australia Markets close in 4 hrs 29 mins

ChromaDex Corporation (CDXC)

NasdaqCM - NasdaqCM Real-time price. Currency in USD
Add to watchlist
2.7600-0.0500 (-1.78%)
At close: 04:00PM EST
2.7600 0.00 (0.00%)
After hours: 06:27PM EST
Full screen
Trade prices are not sourced from all markets
Previous close2.8100
Bid2.7100 x 2900
Ask3.0600 x 1000
Day's range2.7700 - 3.0000
52-week range2.5100 - 23.6600
Avg. volume353,364
Market cap188.485M
Beta (5Y monthly)1.73
PE ratio (TTM)N/A
EPS (TTM)-0.4250
Earnings date08 Mar 2022 - 14 Mar 2022
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target est14.80
  • Business Wire

    ChromaDex Announces Results of New Pilot Clinical Trial Showing Anti-Inflammatory Effects of Nicotinamide Riboside (NR) Supplementation

    LOS ANGELES, January 25, 2022--ChromaDex Corp. (NASDAQ:CDXC) today announced results of the 18th clinical trial on its flagship Niagen® (patented nicotinamide riboside, or "NR") ingredient with promising, peer-reviewed findings reported in the Journal of Clinical Investigation. The study investigated the anti-inflammatory effects of ChromaDex’s proprietary NR ingredient in monocytes (a type of white blood cell) extracted from two groups: young, healthy subjects and patients diagnosed with system

  • Simply Wall St.

    We Think ChromaDex (NASDAQ:CDXC) Can Afford To Drive Business Growth

    We can readily understand why investors are attracted to unprofitable companies. For example, although...

  • Business Wire

    ChromaDex and Designs for Health Partner for New Product Development on Niagen®

    LOS ANGELES, January 20, 2022--ChromaDex Corp. (NASDAQ:CDXC) today announced a supply agreement with Designs for Health, a U.S.-based manufacturer of premium dietary supplements for healthcare practitioners (HCPs). ChromaDex’s proprietary healthy aging ingredient Niagen®, the world’s first and only FDA-safety reviewed and patented form of nicotinamide riboside, will be added to multi-ingredient Designs for Health formulas. The new products will be available exclusively through the company’s exte